Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Operating Margin: 2015-2023

Historic Operating Margin for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to -23,146.22%.

  • Spyre Therapeutics' Operating Margin fell 1955854.00% to -23,146.22% in Q2 2023 from the same period last year, while for Jun 2023 it was -17,587.05%, marking a year-over-year decrease of 1709021.00%. This contributed to the annual value of -27,347.97% for FY2023, which is 2370774.00% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Operating Margin of -23,146.22% as of Q2 2023, which was down 143.70% from -9,497.98% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Operating Margin registered a high of -55.88% during Q2 2021, and its lowest value of -23,146.22% during Q2 2023.
  • Moreover, its 3-year median value for Operating Margin was -3,587.68% (2022), whereas its average is -6,777.45%.
  • Data for Spyre Therapeutics' Operating Margin shows a maximum YoY tumbled of 1,955,854bps (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' Operating Margin (Quarterly) stood at -560.98% in 2021, then tumbled by 1,084,498bps to -11,405.95% in 2022, then slumped by 1,955,854bps to -23,146.22% in 2023.
  • Its Operating Margin stands at -23,146.22% for Q2 2023, versus -9,497.98% for Q1 2023 and -11,405.95% for Q4 2022.